Last year was a downer in so many ways. But, for the oncology community, 2020 also brought plenty of reasons to celebrate.
Americans have postponed cancer screenings and other cancer care to avoid COVID-19 exposure, new data confirms. But they may inadvertently be trading one health risk for another.
Cancer doesn’t stop. So what happens when clinical trials for cancer treatments do? The question looms as the coronavirus brings trials across the country to a halt.
The conversation usually begins with an apology. I need a biopsy, I tell my patient, to see how their cancer has changed and to guide the next steps in treatment.
Precision medicine is often associated with cancer. But the practice of finding the right medicine for the right patient at the right time could also revolutionize the treatment of autoimmune diseases.
Twenty years after an international charter launched the first World Cancer Day, this year’s event allows advocates to reflect on what’s changed – and what hasn’t – in cancer care.
Successfully fighting cancer with innovative treatments requires a patient-centered care approach, notes a new white paper from the Alliance for Patient Access’ Oncology Therapy Access Working Group. But for more people to do the same, policy needs to enable a more patient-centered approach to care.
Medicare beneficiaries nationwide could soon have access to innovative CAR-T cancer therapies – under certain stipulations.
Each year, on the last day of February, Rare Disease Day is celebrated across the globe to raise awareness for those who suffer from complex illnesses. This day is meant to highlight diseases that people continue to fight every day and to promote advancements that are being made to find cures.
About 83 percent of Americans say they could depend upon their health insurer if diagnosed with a serious illness like cancer, according to Aimed Alliance polling.